Eli Lilly and Company (LLY)
VERVE-102 gene-editing catalyst, tirzepatide scale, and valuation at fresh highs
Executive Summary
Eli Lilly closed May 22, 2026 at $1,065, extending a sharp recovery from the late-April trough near $850 and printing a new cycle high on volume above 3.4 million shares. The immediate catalyst is updated Phase 1 data for VERVE-102, Lilly's in vivo PCSK9 base editor acquired through the $1 billion Verve Therapeutics deal: a single infusion cut LDL cholesterol by up to 62% and PCSK9 protein by up to 88%, with durable effects and no treatment-related serious adverse events reported—clearing the efficacy bar set by injectable PCSK9 inhibitors and setting up a Phase 2 launch.
The core franchise remains tirzepatide (Mounjaro / Zepbound), where Lilly still commands the GLP-1/obesity growth narrative alongside a deep oncology and immunology portfolio. Trailing metrics screen rich—~37.8× earnings, 1.66 PEG, ~30.6× price-to-book—but are supported by ~46% operating margins, 81% return on equity, and ~15% revenue growth. Wall Street maintains a Buy consensus with average price targets near $1,166–$1,251, implying 9–17% upside from Friday's close.
Recommendation: Buy (accumulate on pullbacks). VERVE-102 adds a differentiated cardiometabolic optionality layer beyond GLP-1, but the stock trades at the top of its 90-day range with RSI near 69. Long-term holders can scale in; new entries should prefer dips toward the 50-day SMA (~$943) or post-earnings volatility around the August report.
90-Day Price Action
Daily close, 50-day simple moving average, and 14-period Kaufman adaptive moving average (KAMA).
NYSE consolidated closing prices; moving averages computed from those closes.
Company Overview
Eli Lilly and Company, founded in 1876 and headquartered in Indianapolis, is one of the world's largest pharmaceutical manufacturers. The firm discovers, develops, and markets human medicines across cardiometabolic health, oncology, immunology, and neuroscience—with global reach across the United States, Europe, China, and Japan.
The modern Lilly story is anchored in incretin biology: Mounjaro (tirzepatide for type 2 diabetes) and Zepbound (tirzepatide for obesity) have re-rated the entire sector, while legacy diabetes brands (Humalog, Basaglar) and partners like Boehringer Ingelheim on Jardiance provide cash-flow ballast. Oncology contributions include Verzenio, Jaypirca, and Retevmo; immunology spans Taltz, Omvoh, and Olumiant. The 2025 acquisition of Verve Therapeutics added a gene-editing pipeline headlined by VERVE-102, signaling management's intent to own one-time cardiovascular cures—not just chronic injections.
Lilly trades on the NYSE under LLY with a market capitalization near $954 billion, placing it among the largest healthcare names globally and a top-weighted holding in the S&P 500 (~1.3% of SPY).
| Metric | Value |
|---|---|
| Price (May 22, 2026) | $1,065.00 |
| 30-day high / position vs high | $1,070.34 / at high |
| Market cap | ~$954.1B |
| Enterprise value | ~$996.9B |
| Trailing P/E | 37.8 |
| PEG ratio | 1.66 |
| Price / book | 30.6 |
| Dividend yield | 0.59% |
| Free cash flow (TTM, per share) | $15.16 |
| EBITDA (TTM) | ~$33.1B |
| Return on equity (TTM) | 81.0% |
| Debt / equity | 1.54 |
Industry and Market Analysis
Sector context
Large-cap pharma entered mid-2026 with a barbell: GLP-1 leaders (Lilly, Novo Nordisk) continue to capture obesity and diabetes TAM expansion, while gene-editing and RNA medicines redefine cardiovascular and rare-disease economics. VERVE-102 positions Lilly at the intersection—a one-time liver edit that permanently lowers LDL, potentially displacing lifelong statin and PCSK9-inhibitor regimens for high-risk patients. Competitors in incretins face manufacturing and payer hurdles; in gene editing, Lilly's scale and Verve integration provide regulatory and commercialization advantages smaller biotechs lack. The key industry debate is whether mega-cap GLP-1 multiples already embed a decade of growth, or whether cardiometabolic platform breadth (injectable + oral orforglipron + gene edit) justifies premium pricing.
Analyst consensus
Buy — ~28–33 analysts
Rating mix: majority Overweight / Buy; limited Sell coverage
Average price target: ~$1,166–$1,251 (highs near $1,500)
Implied upside ~9–17% vs May 22 close; consensus 2026 EPS estimates near $8.81–$8.91
May 2026 coverage skewed constructive after VERVE-102 readouts, with outlets highlighting Phase 2 preparation and LDL reductions on par with approved PCSK9 antibodies. The bull case stacks tirzepatide revenue compounding, Alzheimer's candidate Kisunla optionality, and pipeline depth across oncology. Bears cite valuation (trailing P/E near 38×), GLP-1 competition from Novo and oral entrants, Medicare pricing pressure, and the long regulatory path for in vivo gene editing—including durability, off-target, and access questions that Phase 1 cannot answer.
Sources: Lilly — VERVE-102 Phase 1 data (PR Newswire); STAT — Eli Lilly gene editor cholesterol study; Fierce Biotech — Phase 2 prep.
Technical Analysis
LLY endured a sharp spring correction—falling from $1,052 (Feb 27) to $850 (Apr 29), a ~19% drawdown—before a V-shaped recovery that reclaimed all moving averages and pushed price to fresh highs. May 22's close at $1,065 sits 13% above the 50-day SMA and 15% above the 200-day SMA, confirming a bullish intermediate trend despite still trading slightly below the 100-day average (~$992).
- RSI (14): ~68.5 — upper neutral / approaching overbought; momentum strong but stretched.
- 50-day SMA: ~$943 — price ~13% above; dynamic support on pullbacks.
- 100-day SMA: ~$992 — next overhead reference if rally pauses.
- 200-day SMA: ~$928 — long-term trend firmly bullish.
- KAMA (14): ~$978 — rising sharply; price extended above adaptive average.
- Stochastic %K: ~89 — overbought territory; consolidation likely.
- Money Flow Index: ~74 — buying pressure elevated.
- Support: $1,000–$1,020 (May consolidation); $943–$950 (50-day cluster).
- Resistance: $1,070 (recent high); psychological $1,100 ahead of earnings.
Fundamental Analysis
Lilly's financial profile reflects best-in-class profitability for a diversified pharma major:
| Metric | TTM / latest | Commentary |
|---|---|---|
| Revenue growth | ~14.8% | Tirzepatide-driven; moderating from hyper-growth but still elite at scale |
| Operating margin | ~45.9% | Among highest in large-cap pharma |
| Gross profit (TTM) | ~$60.3B | Pricing power on GLP-1 franchise |
| EPS (trailing) | ~$28.21 | Supports mid-30s P/E at $1,065 |
| Free cash flow / share | ~$15.16 | FCF yield ~1.4% on price—growth not value |
| Return on equity | ~81% | Exceptional capital efficiency |
| Return on assets | ~21.7% | Asset-light relative to revenue base |
| Debt / equity | ~1.54 | Elevated but manageable given cash generation |
VERVE-102 is not yet modeled in consensus numbers, but the mechanism—a single-course liver base edit inactivating PCSK9—could eventually address heterozygous familial hypercholesterolemia and broader ASCVD prevention markets measured in tens of millions of patients globally. Phase 1 success de-risks the science relative to Verve's earlier candidate (shelved over safety); Phase 2 will test durability, dose, and broader populations. Near term, investors should watch Q2 earnings (expected early August 2026) for tirzepatide script trends, manufacturing capacity commentary, and orforglipron oral GLP-1 progress.
Valuation demands growth delivery: at ~38× trailing earnings and 1.66× PEG, Lilly prices in sustained double-digit EPS expansion. That is plausible if obesity penetration remains early-inning, but leaves little room for GLP-1 share loss or major pricing headwinds. The risk-reward favors holders who can tolerate 10–15% drawdowns; traders chasing highs face mean-reversion risk with RSI and stochastic stretched.
Risk Analysis
| Risk | Impact | Mitigant |
|---|---|---|
| GLP-1 competition & pricing | Revenue miss; multiple compression | First-mover scale; dual GIP/GLP-1 efficacy; manufacturing investments |
| Gene-editing regulatory / safety | VERVE-102 delay or failure | Clean Phase 1 safety; Lilly regulatory expertise; PCSK9 biology validated |
| Valuation at cycle highs | 10–20% pullback on sentiment | Institutional ownership; S&P 500 weight; recurring dividend |
| Medicare / IRA price negotiation | Margin pressure on mature brands | Pipeline freshness; patent runway on tirzepatide |
| Manufacturing constraints | Supply-limited growth | Cap-ex expansion; dual sourcing |
| Technical extension | Short-term profit-taking | Strong fundamentals; buy-the-dip history in GLP-1 leaders |